ArticleColloids and surfaces. B, Biointerfaces2019
Co-delivery of doxorubicin and erlotinib through liposomal nanoparticles for glioblastoma tumor regression using an in vitro brain tumor model.
Article in Colloids and surfaces. B, Biointerfaces, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 70 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
70 citing papers in PubMed, 185 citations in OpenAlex.
- Folic Acid-Conjugated Solid Lipid Nanoparticles for Ratiometric Combination Delivery of Docetaxel and Erlotinib in Triple-Negative Breast Cancer Therapy.AAPS PharmSciTech · 2026Article
- Dual-modified Liposomes Encapsulating Nucleic Acids (pApoE2 or pGFP) for Transport Studies Across a Hydrocortisone-enhanced In Vitro Blood-brain Barrier Model for CNS Therapeutic Screening.Pharmaceutical research · 2025Article
- Glioblastoma at the crossroads: current understanding and future therapeutic horizons.Signal transduction and targeted therapy · 2025Review
- Breaking barriers: exploring blood-brain barrier crossing mechanisms with nanomedicine for effective glioma treatment.3 Biotech · 2025Review
- Engineered nanoparticles as a promising drug delivery system for glioblastoma multiforme treatment.Therapeutic delivery · 2025Review
- Exploring chitosan nanoparticles for enhanced therapy in neurological disorders: a comprehensive review.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- Inhibition of CHI3L1 decreases N-cadherin and VCAM-1 levels in glioblastoma.Pharmacological reports : PR · 2025Article
- Penetratin and Mannose-Functionalized Cannabidiol Lipid Nanoparticles Encapsulating the BDNF Gene Reduce Amyloid-Induced Inflammation.Molecular pharmaceutics · 2025Article
- Synthesis and Characterization of Transferrin and Cell-Penetrating Peptide-Functionalized Liposomal Nanoparticles to Deliver Plasmid ApoE2Molecular pharmaceutics · 2025Article
- Overcoming the blood-brain barrier: targeted delivery strategies for gliomas.Frontiers in pharmacology · 2025Review
- Applications of cell penetrating peptide-based drug delivery system in immunotherapy.Frontiers in immunology · 2025Review
- Intranasal administration of angiotensin receptor shRNA to brain lowers blood pressure in spontaneously hypertensive rats.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2025Article
- Status Quo in the Liposome-Based Therapeutic Strategies Against Glioblastoma: "Targeting the Tumor and Tumor Microenvironment".International journal of molecular sciences · 2024Review
- Targeted Hybrid Nanocarriers as Co-Delivery Systems for Enhanced Cancer Therapy.Advanced pharmaceutical bulletin · 2024Review
- Inhibition of CHI3L1 decreases N-cadherin and VCAM-1 levels in glioblastoma.Research square · 2024Article
- Nanomedicine-induced programmed cell death in cancer therapy: mechanisms and perspectives.Cell death discovery · 2024Review
- Combination chemotherapy via poloxamer 188 surface-modified PLGA nanoparticles that traverse the blood-brain-barrier in a glioblastoma model.Scientific reports · 2024Article
- Article
- Review
- Blood pressure reduction through brain delivery of nanoparticles loaded with plasmid DNA encoding angiotensin receptor shRNA.Molecular therapy. Nucleic acids · 2024Article
10 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Glioma is a highly malignant tumor that starts in the glial cells of brain. Tumor cells reproduce quickly and infiltrate rapidly in high grade glioma. Permeability of chemotherapeutic agents into brain is restricted owing to the presence of blood brain barrier (BBB). In this study, we developed a dual functionalized liposomal delivery system for efficient transport of chemotherapeutics across BBB for the treatment of glioma. Liposomes were surface modified with transferrin (Tf) for receptor targeting, and cell penetrating peptide PFVYLI (PFV) to increase translocation of doxorubicin (Dox) and Erlotinib (Erlo) across the BBB into glioblastoma (U87) tumor cells. In vitro cytotoxicity and hemolysis studies were performed to assess biocompatibility of liposomal nanoparticles. Cellular uptake studies demonstrated efficient internalization of Dox and Erlo in U87, brain endothelial (bEnd.3), and glial cells. In addition, dual functionalized liposomes showed significantly (p < 0.05) higher apoptosis in U87 cells. Significantly (p < 0.05) higher translocation of dual functionalized liposomes across the BBB and delivering chemotherapeutic drugs to the glioblastoma tumor cells inside PLGA-Chitosan scaffold resulted in approximately 52% tumor cell death, using in vitro brain tumor model.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.